Jun 06, 2026
15 MIN READ

GLP-1 Dosing Charts: Key Brand Variations

GLP-1 medications follow distinct dosing schedules that vary by brand, formulation, and individual response. Understanding these protocols helps you work with your provider to find the right starting point and progression for sustained weight loss.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 06, 2026
15 MIN READ

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists like semaglutide and tirzepatide are prescribed using structured dosing schedules designed to minimize side effects while maximizing metabolic benefit. Each formulation—whether injectable, oral, or compounded—follows its own titration pathway, and individual factors including genetics, metabolic history, and gastrointestinal tolerance can influence how quickly a patient advances through dose levels.

How Injectable Semaglutide Dosing Works

Injectable semaglutide follows a four-week titration cycle starting at 0.25 mg weekly, then increasing to 0.5 mg, 1 mg, and potentially 2 mg over successive weeks. This gradual step-up approach allows your body to adapt to the medication while your provider monitors efficacy and tolerability. Most patients experience meaningful appetite suppression and weight loss within the first four weeks, though response varies based on metabolic factors and adherence.

PlexusDx compounded semaglutide injections are prepared in licensed 503A pharmacies to match these clinical protocols, starting at $149 per month regardless of dose level. Your dose may need to go up over time—your price won't. The flat monthly rate removes cost barriers to dose optimization, allowing your provider to titrate based on clinical response rather than financial constraints.

Tirzepatide Injection Schedules and Progression

Tirzepatide, a dual GIP/GLP-1 receptor agonist, uses a four-week titration beginning at 2.5 mg weekly, advancing through 5 mg, 7.5 mg, 10 mg, and up to 15 mg based on individual response. Because tirzepatide targets two distinct peptide pathways rather than one, many patients report stronger appetite reduction and faster metabolic improvements compared to semaglutide alone. Clinical trials show tirzepatide-treated patients achieve 20–22% weight loss at the highest approved doses, compared to 15–18% with semaglutide.

PlexusDx compounded tirzepatide injections begin at $249 monthly with the same fixed-price model across all dose escalations. Genetic factors—particularly variants in the GIP receptor gene (GIPR rs1800437) and GLP-1 receptor gene (GLP1R rs6923761)—can predict which patients show superior response to dual-agonist therapy, information available through the PlexusDx Precision Peptide Genetic Test.

Oral Formulation Dosing Differences

Oral semaglutide and oral tirzepatide follow different dosing rhythms than injectable versions because they must overcome gastrointestinal absorption challenges. Oral semaglutide tablets start at 3 mg daily, titrating upward to 7 mg and 14 mg, while oral tirzepatide begins at 2.5 mg daily and progresses to 5 mg, 10 mg, and 15 mg. Both require specific administration protocols—taking tablets on an empty stomach with limited water—to maximize bioavailability.

Oral formulations appeal to patients who prefer needle-free therapy, though weekly injections typically deliver more consistent drug exposure. PlexusDx oral semaglutide starts at $249 monthly and oral tirzepatide at $279 monthly, each with flat-rate pricing across all dose levels. Absorption differences mean some patients require higher oral doses to achieve results equivalent to lower injectable doses.

Compounded vs. Brand-Name Dosing Protocols

Brand-name semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) follow FDA-established dosing schedules, but compounded versions from licensed 503A pharmacies maintain identical titration protocols and pharmacological action. The key difference is cost and accessibility: compounded medications eliminate branded markups and distribution fees, making progressive dose optimization financially sustainable for patients without insurance coverage.

PlexusDx compounds all GLP-1 medications through verified 503A pharmacies—never 503B facilities—ensuring pharmaceutical-grade preparation and quality control. Dosing decisions depend on clinical response, not price tier, because PlexusDx uses flat monthly rates. A patient whose provider recommends advancing from 0.5 mg to 1 mg semaglutide pays the same $149 monthly fee, enabling evidence-based prescribing free from cost-based barriers.

Personalized Dosing With Genetic Testing

Genetic variation in peptide pathways significantly influences how individual patients respond to GLP-1 therapy and the optimal dose level for their metabolism. Key genetic markers—including FTO rs9939609 (fat mass regulator), MC4R rs17782313 (melanocortin signaling), GIPR rs1800437, and GLP1R rs6923761—predict baseline hunger levels, weight susceptibility, and receptor sensitivity to agonist therapy. Patients carrying risk alleles in the FTO gene may require higher doses or longer titration windows to achieve equivalent metabolic benefit.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after first month of treatment) maps 14 distinct peptide pathways, analyzes 49 individual peptides, and delivers 150+ genetic insights specific to your GLP-1 response profile. This personalized roadmap allows your provider to anticipate dosing needs, select between semaglutide, tirzepatide, or dual-compound therapy (GLP-Squared), and adjust titration speed based on your unique genetic architecture rather than one-size-fits-all protocols.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the standard starting dose for semaglutide injection?

Injectable semaglutide treatment begins at 0.25 mg weekly, then increases by 0.25 mg every four weeks up to a therapeutic dose of 1–2 mg weekly. PlexusDx compounded semaglutide starts at $149 monthly regardless of which dose level your provider prescribes, ensuring you're never charged more as your dose advances.

How does tirzepatide dosing differ from semaglutide?

Tirzepatide starts at 2.5 mg weekly and escalates through 5 mg, 7.5 mg, 10 mg, and 15 mg, following a similar four-week cycle as semaglutide. Because tirzepatide activates both GIP and GLP-1 pathways, many patients advance faster and achieve greater weight loss at equivalent timepoints. Clinical trials show tirzepatide delivers 20–22% weight loss versus 15–18% for semaglutide at maximum approved doses.

Does PlexusDx charge different prices for different dose levels?

No. PlexusDx uses flat monthly pricing—semaglutide injections start at $149/mo, tirzepatide injections at $249/mo—regardless of dose escalation. Your dose may need to go up over time, but your price won't, eliminating financial barriers to dose optimization based on clinical response.

Can oral semaglutide achieve the same results as injections?

Oral semaglutide can produce weight loss and metabolic benefits, but typically requires higher doses (up to 14 mg daily) to match the efficacy of 1–2 mg weekly injections due to lower bioavailability. Oral formulations appeal to needle-averse patients and are available through PlexusDx at $249 monthly, though injectable therapy generally delivers faster, more predictable results.

How does the PlexusDx Precision Peptide Genetic Test personalize dosing?

The test analyzes genetic variants in GLP1R, GIPR, FTO, and MC4R genes that predict your baseline hunger, weight susceptibility, and receptor sensitivity to GLP-1 agonists. Results guide your provider in selecting the right medication (semaglutide, tirzepatide, or dual-compound) and anticipating titration speed, moving beyond population-average dosing schedules to truly personalized therapy optimized for your genetic profile.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves